Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nikhil Meena is active.

Publication


Featured researches published by Nikhil Meena.


Pharmacotherapy | 2016

Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study

Drayton A. Hammond; Melanie Smith; Jacob T. Painter; Nikhil Meena; Katherine Lusardi

The combination of vancomycin and piperacillin‐tazobactam has been associated with an increased risk of acute kidney injury (AKI) in non–critically ill patient populations, but it is still unknown if this association exists in critically ill patients. The objective of this study was to compare the incidence of AKI development during therapy or within 72 hours after completion of therapy in adult critically ill patients who received vancomycin with concomitant piperacillin‐tazobactam or cefepime.


Respirology | 2012

Is chest tube insertion with ultrasound guidance safe in patients using clopidogrel

Wissam Abouzgheib; Yousef Shweihat; Nikhil Meena; Thaddeus Bartter

Background and objective:  Drainage of the pleural space is a common procedure. The safety of chest tube insertion in patients using clopidogrel has not been investigated.


International journal of adolescent medicine and health | 2018

Is vaping a gateway to smoking: a review of the longitudinal studies

Kshitij Chatterjee; Bashar Alzghoul; Ayoub Innabi; Nikhil Meena

Abstract Background: The use of e-cigarettes (ECs) is rising globally. There is concern that e-cigarette may actually lead to smoking, especially amongst adolescents. Objective: To perform a comprehensive review of literature reporting the longitudinal effects of e-cigarette use on onset of smoking among adolescents and young adults. Methods: A search was conducted using PubMed, Google Scholar, Scopus, and Web of Science in February 2016 to identify the studies containing data on EC use among adolescents and young adults (age<30 years). We then narrowed our search to only include longitudinal studies with data on EC and conventional cigarette smoking among this population. Results: Four longitudinal studies were identified that analyzed the use of ECs and smoking at both baseline and follow-ups in the target population. These studies demonstrated that EC use is associated with an increase in combustible cigarette smoking, even amongst the adolescents who were not susceptible to smoking. Conclusion: This review highlights the strong evidence that not only are ECs are not an effective tool for smoking cessation among adolescents, they actually are associated with higher incidence of combustible cigarette smoking. Policy makers need to recognize of the insidious nature of this campaign by the tobacco industry and design policies to regulate it.


Respiration | 2015

Left Adrenal Biopsy Using the Convex Curvilinear Ultrasound Scope

Nikhil Meena; Cidney Hulett; Susanne K. Jeffus; Thaddeus Bartter

Effective use of the convex curvilinear ultrasound bronchoscope in the esophagus (EUS-B) is well described. EUS-B has not been described for diagnostic sampling of the left adrenal gland. We describe 6 cases of diagnostic fine-needle aspiration of the left adrenal gland using EUS-B. This capacity increases the diagnostic capabilities of the pulmonologist experienced in EUS-B.


Cancer Cytopathology | 2016

Rapid onsite evaluation: A comparison of cytopathologist and pulmonologist performance.

Nikhil Meena; Susanne K. Jeffus; Nicole A. Massoll; Eric R. Siegel; Soheila Korourian; Chien Chen; Thaddeus Bartter

Rapid onsite evaluation (ROSE) has several potential benefits but also can prolong procedures if one must wait for a cytopathologist, and it can involve a considerable time commitment on the part of the cytopathologist. At the University of Arkansas for Medical Sciences, interventional pulmonologists have routinely reviewed cytology specimens. This study was performed to determine prospectively how accurately pulmonologists could perform ROSE and whether they could contribute to the efficiency of the process.


Case Reports | 2014

Myasthenia gravis masquerading as dysphagia: unveiled by magnesium infusion

Jagpal S. Klair; Yogita Rochlani; Nikhil Meena

Myasthenia gravis (MG) is a neuromuscular disorder that typically affects the ocular, bulbar, neck, proximal limbs and respiratory muscles. Dysphagia can occasionally be the only presenting symptom leading to extensive but ultimately futile gastrointestinal workup. Delay in diagnosis and use of certain pharmacological agents in the interim can lead to a myasthenic crisis, which though diagnostic is life threatening. We document a case of dysphagia as the only symptom of myasthenia, diagnosed after a magnesium infusion precipitated myasthenic crisis. A 70-year-old Caucasian woman who had had progressive dysphagia for 2 years, for which multiple oesophageal dilations were performed. During a hosptalisation for further gastrointestinal workup, she went into myasthenic crisis (respiratory failure) after receiving magnesium replacement. She required ventilatory support and received five plasma exchange (PLEX) treatments after myasthenia was confirmed by the detection of high antiacetylcholine receptor antibody. Though her symptoms improved, she had a prolonged hospital stay (25 days) and required 18 days of mechanical ventilation. This underscores the morbidity associated with a delay in diagnosis of this condition. This case report suggests that neuromuscular causes should be considered early in elderly patients presenting with dysphagia. Timely diagnosis, initiation of management and avoidance of drugs that affect neuromuscular transmission may help reduce the morbidity and mortality associated with myasthenic crisis.


Journal of Thoracic Disease | 2017

A review of the management of complex para-pneumonic effusion in adults

Vikas Koppurapu; Nikhil Meena

A complex para-pneumonic effusion is a descriptive term for exudative effusions, which complicate or are likely to complicate the anatomy of the pleural space after pneumonia. We performed an online search was performed using the resources PubMed and Google Scholar to provide an update on the management of such effusions based on review of published literature. Search terms including pleural effusion (PE), parapneumonic effusion, and empyema were used. Relevant studies were identified and original articles were studied, compared and summarized. References in these articles were examined for relevance and included where appropriate. Studies involving pediatric patients were excluded. Management of para-pneumonic PE has changed tremendously over the last decade. As we accumulate more evidence in this area, approach to pleural fluid drainage is becoming more specific and guideline based. An example of a practice changing study in this aspect is the Multi-center Intrapleural Streptokinase Trial (MIST) 2 trial which demonstrated that a combination of intra-pleural tPA and DNAse improved outcomes in pleural infections compared to DNase or t-PA alone. More randomized control trials are needed to describe the role of surgical techniques like VATS (video-assisted thoracoscopic surgery) when MIST 2 protocol fails; this combination has revolutionized the management of empyema in recently.


Journal of Intensive Care Medicine | 2017

Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock.

Drayton A. Hammond; Kelsey McCain; Jacob T. Painter; Oktawia A. Clem; Julia Cullen; Amy L. Brotherton; Divyan Chopra; Nikhil Meena

Background: Guidance for the discontinuation of vasopressors in the recovery phase of septic shock is limited. Norepinephrine is more easily titrated; however, septic shock is a vasopressin deficient state, which exogenous vasopressin endeavors to resolve. Discontinuation of vasopressin before norepinephrine may result in clinically significant hypotension. Methods: This retrospective, cohort study compared discontinuation of norepinephrine and vasopressin in medically, critically ill patients in the recovery phase of septic shock from May 2014 to June 2016. Difference in clinically significant hypotension after norepinephrine or vasopressin discontinuation was evaluated with χ2 test. Linear regression was performed, examining the effect of agent discontinuation on clinically significant hypotension. Baseline variables were examined for a bivariate relationship with clinically significant hypotension; those with P < .2 were included in the model. Results: Vasopressin was discontinued first or last in 62 and 92 patients, respectively. Sequential Organ Failure Assessment scores at 72 hours (7.9 vs 7.6, P = .679) were similar. In unadjusted analysis, when vasopressin was discontinued first, more clinically significant hypotension developed (10.9% vs 67.8%, P < .001). There was no difference in intensive care unit (174 vs 216 hours, P = .178) or hospital duration (470 vs 473 hours, P = .977). In adjusted analyses, discontinuing vasopressin first was associated with increased clinically significant hypotension (odds ratio [OR]: 13.837, 95% confidence interval [CI]: 3.403-56.250, P < .001) but not in-hospital (OR: 0.659, 95% CI: 0.204-2.137, P = .488) or 28-day mortality (OR: 0.215, 95% CI: 0.037-1.246, P = .086). Conclusion: Adult patients receiving norepinephrine and vasopressin in the resolving phase of septic shock may be less likely to develop clinically significant hypotension if vasopressin is the final vasopressor discontinued.


Journal of bronchology & interventional pulmonology | 2016

EBUS-TBNA and EUS-FNA: Risk Assessment for Patients Receiving Clopidogrel.

Nikhil Meena; Wissam Abouzgheib; Setu Patolia; Justin Rosenheck; Ziad Boujaoude; Thaddeus Bartter

Background:Clopidogrel is widely used for the prevention of thrombotic vascular complications. Its primary potential toxicity is bleeding. Management of clopidogrel therapy for patients undergoing invasive procedures is an area of ongoing study. We sought to evaluate the bleeding risk for patients undergoing needle aspiration biopsy by endobronchial ultrasound (EBUS) or esophageal ultrasound (EUS) while taking clopidogrel. Methods:Retrospective review of sequential cases of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and esophageal ultrasound fine needle aspiration (EUS-FNA). Results:Three hundred ninety-five consecutive procedures were reviewed. Thirty-seven patients were taking clopidogrel at time of biopsy. The patients taking clopidogrel were significantly older than those in the control group. Two patients (1%) in the control group were admitted for observation, but neither was found to have a significant bleed. There were no clinically significant bleeding complications in either of the study groups. Conclusions:It is reasonable to proceed with EBUS-TBNA or EUS-FNA when both, (1) clopidogrel cannot be stopped and, (2) an important diagnostic question is at stake.


Hospital Pharmacy | 2016

Impact of Targeted Educational Interventions on Clostridium difficile Infection Treatment in Critically Ill Adults

Drayton A. Hammond; Catherine A. Hughes; Jacob T. Painter; Rose E. Pennick; Kshitij Chatterjee; Bradley Boye; Nikhil Meena

Background Clostridium diffcile infection (CDI) is a growing clinical and economic burden throughout the world. Pharmacists often are members of the primary care team in the intensive care unit (ICU) setting; however, the impact of pharmacists educating other health care providers on appropriateness of CDI treatment has not been previously examined. Objective This study was performed to determine the impact of structured educational interventions on CDI treatment on appropriateness of CDI treatment and clinical outcomes. Methods This was a single-center, retrospective, cohort study of patients with CDI in the medical ICU at an academic medical center between January and June 2014 (pre-period) and 2015 (post-period). All patients were evaluated for appropriate CDI treatment before and after implementing pharmacist-provided educational interventions on CDI treatment. Results Patients in the post-period were prescribed appropriate CDI treatment more frequently than patients in the pre-period (91.7% vs 41.7%; p = .03) and received fewer inappropriate doses of a CDI treatment agent (14 doses vs 30 doses). Patients in the pre-period had a shorter ICU length of stay [1.5 days (range, 1–19) vs 3.5 days (range, 2–36); p = .01] and a similar hospital length of stay [9.5 days (range, 4–24) vs 11.5 days (range, 3–56); p = .30]. Total time spent providing interventions was 4 hours. Conclusion Patients had appropriate CDI treatment initiated more frequently in the post-period. This low-cost intervention strategy should be easy to implement in institutions where pharmacists interact with physicians during clinical rounds and should be evaluated in institutions where interactions between pharmacists and physicians occur more frequently in non-rounding situations.

Collaboration


Dive into the Nikhil Meena's collaboration.

Top Co-Authors

Avatar

Thaddeus Bartter

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Kshitij Chatterjee

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Bashar Alzghoul

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Drayton A. Hammond

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ayoub Innabi

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jacob T. Painter

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Brendon Colaco

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Clinton Colaco

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jagpal S. Klair

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Wissam Abouzgheib

University of Arkansas for Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge